Opinion · 6 Jul 2023
Review articlePublished 2013
Thrombosis Therapy: Focus on Antiplatelet Agents
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Platelet adhesion, activation and aggregation to the injured vessel wall are crucially involved in the pathogenesis of thrombus formation. Agents in theory thwarting these phases would have significant clinical value. The current antiplatelet drugs used in daily clinical practice include COX-1 inhibitor aspirin, ADP P2Y12 receptor antagonist clopidogrel, and the GPIIb-IIIa antagonists (abciximab, eptifibatide and tirofiban). However, confined curative ratio along with unforeseen bleeding risk remains a major puzzle of antiplatelet therapy. With advances in understanding of the molecular basis of platelet in thrombosis, newer antiplatelet agents that targets different stage of thrombus formation have been recently developed, mostly including agents targeting platelet adhesion (GPIV, vWF), activation (GPVI, P2Y12, TPα, PAR1, phosphodiesterase, cyclooxygenase), and aggregation (GPIIb/IIIa). In this article, we will review the advantages and limitations of various antiplatelet agents that have been approved by the US Food and Drug Administration (FDA) or under development.
Subjects
Genetics & Molecular BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Short communication · 1 Nov 2023
Minimizing Stent Thrombosis with Drug-eluting Stent and Dual-Antiplatelet Therapy
Article · 30 Sep 2024
The Comparative Efficacy of Dual and Triple Antiplatelet Therapy in the Prevention of Thrombosis Following Percutaneous Coronary Intervention
Case report · 9 May 2016
Favourable Late Outcome of Percutaneous Coronary Intervention Combined with Aggressive Antiplatelet and Anticoagulant Therapy in Patient with Early Thrombosis in Venous Aortocoronary Bypass Grafts
Research article · 8 May 2023
Use of Antiplatelet and Lipid Lowering Agent Therapies as Primary Cardiovascular Disease Prevention Strategy and their Determinant Factors among Type 2 Diabetes Mellitus Patients in University of Gondar Comprehensive Specialized Hospital, Gondar: A Prospective Cross- Sectional Study
More from this journal
The newest in Journal of Clinical & Medical Genomics.
Opinion · 30 Jun 2026
Next-generation Sequencing: Revolutionizing Clinical Genomics and Personalized Medicine
Article · 19 Feb 2026
Recent Trends in Gene Editing Technology CRISPR Cas9
Opinion · 29 Dec 2025
Genome Annotation: Powering Clinical Genomics and Personalized Medicine
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical & Medical Genomics
- SubjectGenetics & Molecular Biology
- BylineArticles whose byline prints “Fang Jing”
- BylineArticles whose byline prints “Wei Zhang”

